These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32880939)

  • 1. Telomere length, epidemiology and pathogenesis of severe COVID-19.
    Tsilingiris D; Tentolouris A; Eleftheriadou I; Tentolouris N
    Eur J Clin Invest; 2020 Oct; 50(10):e13376. PubMed ID: 32880939
    [No Abstract]   [Full Text] [Related]  

  • 2. The laboratory tests and host immunity of COVID-19 patients with different severity of illness.
    Wang F; Hou H; Luo Y; Tang G; Wu S; Huang M; Liu W; Zhu Y; Lin Q; Mao L; Fang M; Zhang H; Sun Z
    JCI Insight; 2020 May; 5(10):. PubMed ID: 32324595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is COVID-19 more severe in older men?
    Liang X
    Postgrad Med J; 2020 Jul; 96(1137):426. PubMed ID: 32404490
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
    Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
    Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
    Urra JM; Cabrera CM; Porras L; Ródenas I
    Clin Immunol; 2020 Aug; 217():108486. PubMed ID: 32479985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection.
    Altmann DM; Boyton RJ
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2: a storm is raging.
    Pedersen SF; Ho YC
    J Clin Invest; 2020 May; 130(5):2202-2205. PubMed ID: 32217834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.
    Jeannet R; Daix T; Formento R; Feuillard J; François B
    Intensive Care Med; 2020 Sep; 46(9):1769-1771. PubMed ID: 32514592
    [No Abstract]   [Full Text] [Related]  

  • 9. Why is SARS-CoV-2 infection milder among children?
    Palmeira P; Barbuto JAM; Silva CAA; Carneiro-Sampaio M
    Clinics (Sao Paulo); 2020; 75():e1947. PubMed ID: 32428111
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.
    Omran HM; Almaliki MS
    J Infect Public Health; 2020 Sep; 13(9):1196-1201. PubMed ID: 32534944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Grifoni A; Weiskopf D; Ramirez SI; Mateus J; Dan JM; Moderbacher CR; Rawlings SA; Sutherland A; Premkumar L; Jadi RS; Marrama D; de Silva AM; Frazier A; Carlin AF; Greenbaum JA; Peters B; Krammer F; Smith DM; Crotty S; Sette A
    Cell; 2020 Jun; 181(7):1489-1501.e15. PubMed ID: 32473127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of cell-mediated immunity in COVID-19 - An opinion.
    Iqbal H
    Med Hypotheses; 2020 Oct; 143():110152. PubMed ID: 32759017
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphopenia in COVID-19: Therapeutic opportunities.
    Fathi N; Rezaei N
    Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological features of coronavirus disease 2019 in patients with cancer.
    Thibaudin M; Fumet JD; Bon M; Hampe L; Limagne E; Ghiringhelli F
    Eur J Cancer; 2020 Nov; 139():70-80. PubMed ID: 32977223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Effective COVID-19 Vaccine Needs to Engage T Cells.
    Sauer K; Harris T
    Front Immunol; 2020; 11():581807. PubMed ID: 33117391
    [No Abstract]   [Full Text] [Related]  

  • 16. Telomeres and COVID-19.
    Aviv A
    FASEB J; 2020 Jun; 34(6):7247-7252. PubMed ID: 32427393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the genetics and immunopathogenesis of COVID-19.
    Jacob CO
    Clin Immunol; 2020 Nov; 220():108591. PubMed ID: 32920210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune characteristics of severe and critical COVID-19 patients.
    Yang L; Gou J; Gao J; Huang L; Zhu Z; Ji S; Liu H; Xing L; Yao M; Zhang Y
    Signal Transduct Target Ther; 2020 Aug; 5(1):179. PubMed ID: 32868756
    [No Abstract]   [Full Text] [Related]  

  • 19. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.
    Thevarajan I; Nguyen THO; Koutsakos M; Druce J; Caly L; van de Sandt CE; Jia X; Nicholson S; Catton M; Cowie B; Tong SYC; Lewin SR; Kedzierska K
    Nat Med; 2020 Apr; 26(4):453-455. PubMed ID: 32284614
    [No Abstract]   [Full Text] [Related]  

  • 20. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.
    Kang CK; Han GC; Kim M; Kim G; Shin HM; Song KH; Choe PG; Park WB; Kim ES; Kim HB; Kim NJ; Kim HR; Oh MD
    Int J Infect Dis; 2020 Aug; 97():313-321. PubMed ID: 32492530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.